Company News

Industry News

Company News

Industry News

06

2025-11

【Public Health Hotspot】Over 3,000 Cases of Chikungunya Fever! Rapid Testing Technology Powers Precise Prevention and Control, Safeguarding the Health Defense Line

In the face of the threat posed by chikungunya fever, the chikungunya virus nucleic acid detection kit (PCR–fluorescent probe method) independently developed by Guangzhou Weiboxin Biotechnology Co., Ltd. has become a “secret weapon” on the front lines of disease control!

2025-11-06

【Public Health Hotspot】Over 3,000 Cases of Chikungunya Fever! Rapid Testing Technology Powers Precise Prevention and Control, Safeguarding the Health Defense Line

06

2025-11

[Weiboxin] Beware of Gattavirus (GETV): An Invisible Threat to Pig Farms and Scientific Prevention and Control Strategies

In the face of the threat posed by Gata virus, early diagnosis and prevention are critical. We recommend that pig farmers closely monitor the health of their herds, promptly conduct laboratory testing upon detection of suspected clinical signs, and implement timely intervention measures.

2025-11-06

[Weiboxin] Beware of Gattavirus (GETV): An Invisible Threat to Pig Farms and Scientific Prevention and Control Strategies

01

2025-03

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

01

2025-03

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry-wide upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

01

2025-03

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!

2025-03-01

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

01

2025-03

Good News! Another Stem Cell Clinical Research Project Has Been Approved by the National Health Commission

Regenerative medicine technologies, exemplified by stem cell technology, represent the “third medical revolution” following pharmacological and surgical therapies. Stem cells possess the remarkable ability to differentiate into and form any type of tissue in vivo, as well as to self-renew and generate additional stem cells, making them a key frontier area of international medical research in recent years.

2025-03-01

Good News! Another Stem Cell Clinical Research Project Has Been Approved by the National Health Commission
< 1...10111213 >

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home